An Open-label Extension Study To Evaluate The Safety Of Rivipansel (Gmi-1070) In The Treatment Of One Or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease

Trial Profile

An Open-label Extension Study To Evaluate The Safety Of Rivipansel (Gmi-1070) In The Treatment Of One Or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Rivipansel (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Sep 2017 Planned End Date changed from 1 Jul 2020 to 13 Jul 2020.
    • 05 Sep 2017 Planned primary completion date changed from 1 Jul 2020 to 13 Jul 2020.
    • 14 Mar 2017 Planned End Date changed from 1 Jan 2020 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top